Study Aims to Identify Women with Ovarian Cancer Who May Benefit from Maintenance Treatment

Study Aims to Identify Women with Ovarian Cancer Who May Benefit from Maintenance Treatment
Myriad Genetics and AstraZeneca have expanded their collaboration to conduct a study to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza (olaparib) and Avastin (bevacizumab). Myriad’s myChoice HRD Plus is a test for BRCA1 and BRCA2 tumor status, as well as tumor genomic instability status – the frequency at which mutations are found within the genome. Genome instability is thought to be central for the development of cancer in humans. Cells have several DNA repair mechanisms. When one is impaired, as happens when BRCA genes are mutated, they rely on other enzymes, like poly ADP ribose polymerase (PARP), to have their DNA repaired. Therefore, tumors with BRCA mutations are highly susceptible to PARP inhibitors, such as Lynparza. Similarly, tumors with high genomic instability require a functioning PARP pathway. Blocking this enzyme causes cancer cells to accumulate too much DNA errors and die. Under the agreement, Myriad will use its myChoice test as a potential addition to other diagnostic tools in an ongoing Phase 3 clinical trial to help identify patients with faulty DNA repair. Myriad's myChoice is designed to detect when a tumor has lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum chemotherapy or PARP inhibitors. The newest formulation of Lynparza ta
Subscribe or to access all post and page content.